Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (131-140 of 858) with videos related to

Pageof 86
Sort By:
Journal of General Internal Medicine|March 14, 2007
Gender differences in aspirin use among adults with coronary heart disease in the United StatesAlexander R Opotowsky, J Michael McWilliams, Christopher P Cannon
American Heart Journal|October 31, 2007
New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?John P Morrow, Christopher P Cannon, James A Reiffel
JAMA Cardiology|January 3, 2020
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-ReplyRichard G Bach, Christopher P Cannon, Michael A Blazing
Current Atherosclerosis Reports|May 24, 2023
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?Mario Enrico Canonico, Connie N Hess, Christopher P Cannon
Current Atherosclerosis Reports|November 16, 2007
Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patientsChristopher T Dibble, Eli V Gelfand, Christopher P Cannon
The New England Journal of Medicine|February 1, 2018
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationChristopher P Cannon, Gregory Y H Lip, Jonas Oldgren
Circulation. Cardiovascular Interventions|July 17, 2020
Novel Oral Anticoagulants Following Percutaneous Coronary InterventionBryan Q Abadie, Christopher P Cannon, Matthew A Cavender
JAMA|March 16, 2018
Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA RecommendationsIan H de Boer, George Bakris, Christopher P Cannon
Critical Pathways in Cardiology|October 13, 2011
Results of a survey assessing provider beliefs of adherence barriers to antiplatelet medicationsGary C Bird, Christopher P Cannon, Richard H Kennison
European Heart Journal Open|September 19, 2022
Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?Pierre Sabouret, Denis Angoulvant, Christopher P Cannon, et al.
Pageof 86

Showing results (131-140 of 858) with videos related to

Sort By:
Pageof 86
Journal of General Internal Medicine|March 14, 2007
Gender differences in aspirin use among adults with coronary heart disease in the United StatesAlexander R Opotowsky, J Michael McWilliams, Christopher P Cannon
American Heart Journal|October 31, 2007
New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?John P Morrow, Christopher P Cannon, James A Reiffel
JAMA Cardiology|January 3, 2020
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-ReplyRichard G Bach, Christopher P Cannon, Michael A Blazing
Current Atherosclerosis Reports|May 24, 2023
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?Mario Enrico Canonico, Connie N Hess, Christopher P Cannon
Current Atherosclerosis Reports|November 16, 2007
Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patientsChristopher T Dibble, Eli V Gelfand, Christopher P Cannon
The New England Journal of Medicine|February 1, 2018
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationChristopher P Cannon, Gregory Y H Lip, Jonas Oldgren
Circulation. Cardiovascular Interventions|July 17, 2020
Novel Oral Anticoagulants Following Percutaneous Coronary InterventionBryan Q Abadie, Christopher P Cannon, Matthew A Cavender
JAMA|March 16, 2018
Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA RecommendationsIan H de Boer, George Bakris, Christopher P Cannon
Critical Pathways in Cardiology|October 13, 2011
Results of a survey assessing provider beliefs of adherence barriers to antiplatelet medicationsGary C Bird, Christopher P Cannon, Richard H Kennison
European Heart Journal Open|September 19, 2022
Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?Pierre Sabouret, Denis Angoulvant, Christopher P Cannon, et al.
Pageof 86